Rifasutenizol

Antibiotic medication

Rifasutenizol
[[File: Chemical structure of Rifasutenizol |frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Rifasutenizol is a broad-spectrum antibiotic used primarily in the treatment of bacterial infections. It belongs to the class of antibiotics known as rifamycins, which are known for their effectiveness against Mycobacterium tuberculosis and other mycobacteria.

Mechanism of Action

Rifasutenizol works by inhibiting bacterial RNA polymerase, an enzyme critical for the transcription of DNA into RNA. This inhibition prevents the bacteria from synthesizing essential proteins, ultimately leading to their death. The drug binds to the beta subunit of the RNA polymerase, which is a mechanism similar to other rifamycins.

Pharmacokinetics

Rifasutenizol is well absorbed when administered orally, with peak plasma concentrations occurring approximately 2 hours after ingestion. It is widely distributed throughout the body, including the central nervous system, which makes it effective in treating meningitis caused by susceptible organisms. The drug is metabolized in the liver and excreted primarily in the bile.

Clinical Uses

Rifasutenizol is indicated for the treatment of various bacterial infections, including:

• Tuberculosis
• Leprosy
• Brucellosis
• Legionnaires' disease

It is often used in combination with other antibiotics to prevent the development of antibiotic resistance.

Side Effects

Common side effects of rifasutenizol include:

• Nausea
• Vomiting
• Diarrhea
• Rash

Serious side effects may include hepatotoxicity, hypersensitivity reactions, and hematological disorders. Patients are advised to monitor liver function regularly during treatment.

Drug Interactions

Rifasutenizol can interact with several other medications, including:

• Anticoagulants
• Oral contraceptives
• Antiretroviral drugs

These interactions may reduce the effectiveness of the co-administered drugs or increase the risk of adverse effects.

Related Pages

• Antibiotic resistance
• Rifampicin
• Mycobacterium tuberculosis